Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Valeant Pharmaceuticals International, Inc. (VRX) -NYSE ? Watchlist 37.59 Up 3.42(10.02%) 9:36AM EDT - Nasdaq Real Time Price
je zal ze vorige week maar hebben weggedaan.
mooi nws voor pharm.ze nemen de hele markt over let maar op!
men legt de nadruk op NOT BLOOD BASED!!!
Leuk voor een ritje, voor de rest afwachten wat voor zoden het aan de dijk zet.
Koop advies Eindelijk OMHOOG
Jasje schreef op 7 april 2016 16:18 :
Koop advies
Eindelijk
OMHOOG
De analisten van THEODOOR GILISSEN die Pharming al 25 jaar doorlichten/volgen, hebben een VERKOOP advies afgegeven met als KOERSDOEL € 0,00
Zie dat degene die al langer in Pharming zitten van de gelegenheid gebruik maken om hun aandelen te verkopen, en wie Pharming de laatste mnd. gevolgd heeft begrijpt dat volkomen. Pharming soms moet je ze hebben maar meestal niet, komt steeds vaker uit.
je hoeft ze niet te kopen hoor haha, ga je toch lekker wat anders doen met je poen.bye bye
Valeant CEO Pearson may be held in contempt Apr 10 2016, 08:18 ET | By: Yoel Minkoff, SA News Editor More trouble at Valeant Pharmaceuticals (NYSE:VRX)... A Senate committee may soon start contempt proceedings against the drugmaker's chief executive. "Michael Pearson was under subpoena to appear for a deposition today related to the Senate Special Committee on Aging's drug pricing investigation, and he did not comply with that subpoena," Senators Susan Collins and Claire McCaskill said late Friday. "It is our intent to initiate contempt proceedings against him."
Big deal, hij gaf geen gehoor aan zn Getuigenoproep. a writ issued by court authority to compel the attendance of a witness at a judicial proceeding; disobedience may be punishable as a contempt of court Poepoe minachting van het hof.
Valeant vraagt topman mee te werken met onderzoek AMSTERDAM -- Valeant Pharmaceuticals heeft de vertrekkend topman Michael Pearson gevraagd om mee te werken met een onderzoek naar de prijsstelling van medicijnen. Dit maakte de farmaceut maandag bekend. Pearson liet vrijdag een dagvaarding van een Amerikaanse onderzoekscommissie onbeantwoord. Verschillende onderzoeken lopen in de Verenigde Staten volgens persbureau Reuters tegen Valeant vanwege een "agressieve" prijsstrategie en discutabele boekhoudpraktijken. Valeant maakte onder CEO Pearson een sterke groei door, gesteund door een flink aantal overnames. Deze transacties gingen volgens Reuters in veel gevallen gepaard met scherpe prijsstijgingen van medicijnen. Pearson zal vertrekken als bestuursvoorzitter wanneer de farmaceut een vervanger heeft gevonden. Valeant vroeg ook bestuurslid en voormalig financieel directeur Howard Schiller op te stappen, maar dit weigert Schiller. Het aandeel Valeant Pharmaceuticals noteerde maandag 6,4 procent lager op 31,50 dollar. Door ABM Financial News. Info@abmfn.nl: +31(0)20-26 28 999
One of Valeant's creditors not playing ball, calls a default on debt; shares down 6% after hours Apr 12 2016, 16:38 ET | Business Insider reports that one of Valeant Pharmaceuticals' (NYSE:VRX) creditors has apparently informed the company that it will call a default on its debt. Shares are down 6% after hours on robust volume.
Beur schreef op 12 april 2016 22:53 :
One of Valeant's creditors not playing ball, calls a default on debt; shares down 6% after hours
Apr 12 2016, 16:38 ET |
Business Insider reports that one of Valeant Pharmaceuticals' (NYSE:VRX) creditors has apparently informed the company that it will call a default on its debt. Shares are down 6% after hours on robust volume.
Update: In a statement, Valeant reports that it has received a notice of default from holders of its 5.5% Notes due 2023 as a result of the delay in filing its 10-K. If the company files the document by June 11, it will cure the default. Its current target date for filing is April 29 so there appears to be ample time to resolve the issue.
A Merger And Acquisition/Tax Inversion Idea That Will Probably Never Happen, But Should $VRXwww.seekingalpha.com/article/3965207 Even those who are not avid investors have seen the developments in Valeant Pharmaceuticals International Inc. (NYSE:VRX), as it has been plastered across every newspaper for months now. Valeant is an interesting story. For people unfamiliar with the company's revenue model, it basically grows by acquiring other companies, or the rights to drugs it believes will be successful. A year after the market crash in 2008, it began a meteoric rise, gaining over 1K% into 2015. But then something astonishing happened. The sketchy and unethical secret life of CEO Michael Pearson started to unravel and become public. The business model also started to show its weaknesses as many drugs failed expectations, or were purchased at close to its peak market cycle. Valeant's market cap has fallen 87% from last summer and has lost $80 Billion in market cap. Trading at around $260 a share not even a year ago, the stock now trades at $33 a share. The selling pressure is relentless and the stock plummeted over 50% in one day on March 15. The fall was due to Valeant announcing that it reduced earnings and revenue projections, and said that its continuing inability to file its annual financial report could lead to default on $30 billion of debt because of covenants it has with lenders. To make matters worse, many big bondholders are calling for default, the balance sheet is a mess, and the company has come under attack from Andrew Left of Citron Research who is a famed short seller. Forbes playfully described Valeant's financial statement as "financial-statement gymnastics" and that the "tone at the top of the organization bears too much resemblance to those of Enron, Tyco and WorldCom for comfort." The situation gets more interesting as famed Hedge Fund Manager Bill Ackman of Pershing Square Capital Management (who owns the largest position in Valeant shares) has muscled his way onto the board, and kicked out the CEO, looking for a suitable replacement. However, it doesn't stop there. Jeffrey Ubben, CEO of the Hedge Fund ValueAct, has disagreed with Ackman over the direction of the company and it now looks as though things might get messy between the two. But I have an idea for Bill and Jeff: force a potential merger with, or sale to Mallinckrodt PLC (NYSE:MNK). Mallinckrodt is engaged in the specialty pharmaceuticals business, just like Valeant. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals sector includes branded and generic drugs, and the Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland. I think you know where I am going with this now. The U.S. Corporate Tax Rate is 35%, one of the highest in the world. This is why many companies have opted for tax inversions to help relocate their headquarters abroad, adopting the [low] tax policies of their new host countries. One of the hottest areas to relocate has been Ireland, which has an extremely low 12.5% rate, making it very business friendly. There have been many high profile tax inversions and attempts in the last few years. Medtronic (NYSE:MDT) bought Covidien and relocated to Dublin. Walgreens (now Walgreens Boots Alliance WBA) was thinking of moving its headquarters to extremely tax friendly Switzerland, which has a corporate tax rate of 8.5%, but ultimately decided against it, purportedly because it would have cost taxpayers billions of dollars. The most recent and high profile attempted tax inversion was the mega-merger between Pfizer (NYSE:PFE) and Allergan (NYSE:AGN) which looked ready to go even with public outcry until the US Treasury Department created new rules which would make it harder to invert, leading the deal to be canceled. Although not an inversion, in a similar vein, Apple (NASDAQ:AAPL) holds around 200B in cash owned by Apple's subsidiaries in Knocknaheeny, a rundown northern suburb of Cork, Ireland, and has no plans of repatriating that money because of the huge taxes they would have to pay. That is a shame to me, especially as a shareholder. Simple fix: lower the tax rate. If we lowered the US tax rate to somewhere in the range of 20-25%, fewer companies would attempt to invert, more companies would be willing and happy to keep their headquarters in the US, and may even bring cash back to the US. Pfizer tried to move its headquarters to London in 2014 with its attempted takeover of AstraZeneca plc (NYSE:AZN). Obviously, that didn't pan out for Pfizer. It seems Pfizer has had bad luck lately. If certain candidates (wink, wink) named Hillary or Bernie are elected, they may raise the corporate tax rate because they think corporations are "too greedy," as Bernie Sanders just did today in reference to the Verizon (NYSE:VZ) strike. This may cause a race to the exits with companies doing whatever they can to relocate abroad. I'm totally opposed to this approach and believe that Trickle Down Economics is the best way to stimulate an economy. But I won't get into the politics of it here. Mallinckrodt has taken a beating as well because of its similarity with Valeant. Mark Trudeau, the CEO of Mallinckrodt, has stated that Mallinckrodt is not Valeant. He claims they are a strong company, and has pointed to many key factors to explain why he believes his company is positioned for strong growth: • Net Sales up 20% • EPS up 17% • Solid balance sheet and strong FCF • Raised EPS guidance for the year He frantically called into CNBC to defend the company after an interview between Melissa Lee and Andrew Left (the same short seller who put out a research note bashing Valeant) created some serious headlines (Left said that "Valeant Looks Like a Choirboy Next to Mallinckrodt"). This was the same kind of language that drove Valeant's shares to fall off a cliff. Some may find his remarks purely malicious; but many of his calls [e.g. Mobileye (NYSE:MBLY), Valeant, and Mallinckrodt), have been right. You can watch the interview, or should I say sparring match, here. I believe the merger of Mallinckrodt acquiring Valeant as it continues to become cheaper is a win-win-win-win. It's a win for the major hedge funds, a win for both companies merging, and a win for the shareholders. By merging, there will be cost synergies, they will expand their drug portfolio, will pay less in taxes by relocating its tax headquarters to Ireland, and increase revenue. Mallinckrodt has boosted their share buyback to $350M, and their main drug Acthar has continued to grow in sales with potential uses for a wide variety of illnesses. The government has made it harder to invert, but it is still possible. In this situation, it might be worth both companies trying to test the new regulations. Together I believe the new "Valeantckrodt" could become a formidable player in the specialty pharmaceutical arena as it combines similar business models, and Valeant gets the new CEO Ackman is looking for in the form of a new more stable company run by Mark Trudeau.
Reuters: Valeant turning to investment banks to consider options Apr 14 2016, 18:54 ET | Valeant (VRX -2.2%) is up 1.5% after hours as Reuters reports that it's calling in investment banks to go over its options, the clearest signal yet that divestments are coming as it faces down $30B in debt.Goldman Sachs and Centerview Partners are among advisers being consulted.A number of inquiries have come in since CEO Michael Pearson and Pershing Square's Bill Ackman said the firm would consider unloading noncore assets, sources said.Bidders are reportedly kicking the tires on its biggest gastrointestinal product, Xifaxin, as well as aesthetics products Obagi and Solta and skin care product CeraVe. Het begin van de ontmanteling?
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was downgraded by TheStreet from a “hold” rating to a “sell” rating in a research note issued on Friday, Analyst Ratings Network.com reports. Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 33.34 on Friday. Valeant Pharmaceuticals Intl has a 1-year low of $25.27 and a 1-year high of $263.81. The stock has a market cap of $11.44 billion and a PE ratio of 19.15. The stock’s 50 day moving average is $41.89 and its 200-day moving average is $87.61. Valeant Pharmaceuticals Intl (NYSE:VRX) last released its earnings results on Tuesday, March 15th. The specialty pharmaceutical company reported $2.50 earnings per share for the quarter, missing the consensus estimate of $2.61 by $0.11. The business had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.75 billion. During the same period last year, the firm posted $2.58 EPS. Valeant Pharmaceuticals Intl’s revenue was up 22.3% compared to the same quarter last year. On average, analysts predict that Valeant Pharmaceuticals Intl will post $8.79 EPS for the current fiscal year. Several hedge funds and institutional investors recently modified their holdings of VRX. Paulson & CO. Inc. boosted its position in shares of Valeant Pharmaceuticals Intl by 49.2% in the fourth quarter. Paulson & CO. Inc. now owns 13,265,900 shares of the specialty pharmaceutical company’s stock worth $1,348,479,000 after buying an additional 4,375,900 shares during the last quarter. Brahman Capital Corp. boosted its position in shares of Valeant Pharmaceuticals Intl by 102.3% in the fourth quarter. Brahman Capital Corp. now owns 8,117,753 shares of the specialty pharmaceutical company’s stock worth $825,170,000 after buying an additional 4,104,202 shares during the last quarter. Norges Bank bought a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $264,897,000. Price T Rowe Associates Inc. MD boosted its position in shares of Valeant Pharmaceuticals Intl by 9.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 21,853,814 shares of the specialty pharmaceutical company’s stock worth $2,220,949,000 after buying an additional 1,806,903 shares during the last quarter. Finally, Iridian Asset Management LLC CT boosted its position in shares of Valeant Pharmaceuticals Intl by 59.2% in the fourth quarter. Iridian Asset Management LLC CT now owns 4,324,602 shares of the specialty pharmaceutical company’s stock worth $439,596,000 after buying an additional 1,607,834 shares during the last quarter. VRX has been the subject of several other research reports. RBC Capital reiterated a “sector perform” rating and set a $65.00 target price (down previously from $69.00) on shares of Valeant Pharmaceuticals Intl in a research note on Monday, April 11th. JPMorgan Chase & Co. restated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, March 16th. TD Securities lowered shares of Valeant Pharmaceuticals Intl from a “buy” rating to a “hold” rating and lowered their price target for the stock from $155.00 to $110.00 in a research report on Monday, February 29th. Deutsche Bank restated a “hold” rating on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, March 2nd. Finally, Rodman & Renshaw restated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, March 22nd. Seven research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $90.44. Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (NYSE:VRX) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.
Al die adviezen hadden ze een jaar geleden moeten geven. Achteraf is makkelijk!!
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)